Get started
Author

Clara Armengol

Observed name: C. Armengol
Institution: AstraZeneca (Spain)
OpenAlex ID: A5091059469
The Quail Mesonephros: A New Model for Renal Senescence?
2006 · Víctor Nacher, Ana Carretero, et al. · Journal of Vascular Research · 49
Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases
2016 · Montse Erra, Joan Taltavull, et al. · ACS Medicinal Chemistry Letters · 30
Morphological characterization of pecteneal hyalocytes in the developing quail retina
2009 · Cristina Llombart, Víctor Nacher, et al. · Journal of Anatomy · 25
PDF
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
2024 · Adelaide A. Hebert, Carsten Flohr, et al. · Journal of Dermatological Treatment · 23
Pharmacological characterization of CRTh2 antagonist LAS191859: Long receptor residence time translates into long-lasting in vivo efficacy
2016 · Marta Calbet, Miriam Andrés, et al. · Pharmacological Research · 13
Carbohydrate characterization of quail primordial germ cells during migration and gonadal differentiation
2006 · Clara Armengol, Ana Carretero, et al. · Journal of Anatomy · 11
β‐Catenin expression during vascular development and degeneration of avian mesonephros
2005 · Víctor Nacher, Ana Carretero, et al. · Journal of Anatomy · 11
PDF
Physiologic Effects of Housing Rats in Metabolic Cages
2022 · Marta Giral, Clara Armengol, et al. · Comparative Medicine · 8
Discovery of a novel class of zwitterionic, potent, selective and orally active S1P1 direct agonists
2012 · Nuria Aguilar, Marta Mir, et al. · Bioorganic & Medicinal Chemistry Letters · 5
Effects of Changing to Individually Ventilated Caging on Guinea Pigs (Cavia porcellus).
2015 · Marta Giral, Clara Armengol, et al. · PubMed · 4
619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)
2024 · Richard B Warren, Marjolein de Bruin-Weller, et al. · British Journal of Dermatology · 2
Budesonide/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study
2026 · David J. Jackson, Robert A. Wise, et al. · ERJ Open Research · 1
Annual Meeting of the German Society for Microcirculation and Vascular Biology. Munich, Germany, October 12–14, 2006
2006 · Laura V. Gatica, Ana Carretero, et al. · Journal of Vascular Research · 1
PDF
Budesonide/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled asthma: phase 3 LITHOS study
2026 · Alberto Papi, Robert A. Wise, et al. · ERJ Open Research
51887 Lebrikizumab Demonstrates Sustained Efficacy in Adolescent Patients Through 2 Years of Continuous Treatment: Results From ADjoin Long-Term Extension
2024 · Amy Paller, Antonio Torrelo, et al. · Journal of the American Academy of Dermatology
PDF
Discovery of a Potent, Selective, and Orally Available PI3K delta Inhibitor for the Treatment of Inflammatory Diseases.
2017 · Montse Erra, Joan Taltavull, et al. · ACS Medicinal Chemistry Letters
353 Mouse model of cutaneous adverse effects: Validation with human topical therapies
2016 · M. Pont, M. Aulí, et al. · Journal of Investigative Dermatology
PDF
Subject Index Vol. 43, 2006
2006 · Laura V. Gatica, Ana Carretero, et al. · Journal of Vascular Research
PDF
Thanks to the Reviewers
2006 · Laura V. Gatica, Ana Carretero, et al. · Journal of Vascular Research
PDF
Author Index Vol. 43, 2006
2006 · Laura V. Gatica, Ana Carretero, et al. · Journal of Vascular Research
PDF
Membership of the ESM
2006 · Laura V. Gatica, Ana Carretero, et al. · Journal of Vascular Research
PDF
EphrinB2 mRNA expression during chick mesonephros development and degeneration
2001 · Ana Carretero, María José Valderrama, et al. · DIGITAL.CSIC (Spanish National Research Council (CSIC))
Works count: 22
Citation count: 183
H-index: 8
I10-index: 7
Year
Topic
Type